Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia

B-cell chronic lymphocytic leukaemia (B-CLL) remains an incurable disease due to the high risk of relapse, even after complete remission, raising the need to control and eliminate residual tumor cells in long term. Adoptive T cell therapy with genetically engineered specificity is thought to fulfil...

Descripción completa

Detalles Bibliográficos
Autores principales: Koehler, Philipp, Schmidt, Patrick, Hombach, Andreas A., Hallek, Michael, Abken, Hinrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152962/
https://www.ncbi.nlm.nih.gov/pubmed/21837241
http://dx.doi.org/10.1155/2012/595060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152962/
https://www.ncbi.nlm.nih.gov/pubmed/21837241
http://dx.doi.org/10.1155/2012/595060

Ejemplares similares